Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $317

摩根士丹利维持银休特(PODD.US)买入评级，上调目标价至317美元

moomoo资讯 · 2024/11/11 21:37 · 评级/大行评级

Morgan Stanley analyst Patrick Wood maintains $Insulet (PODD.US)$ with a buy rating, and adjusts the target price from $234 to $317.

According to TipRanks data, the analyst has a success rate of 50.0% and a total average return of 6.8% over the past year.

AnalystRecentRatingAutoNews_206393_20241111_833ee7dacd300073de4801116073d624d27a7187_1731407587762980_mm_en

Furthermore, according to the comprehensive report, the opinions of $Insulet (PODD.US)$'s main analysts recently are as follows:

Insulet was recognized for its robust third-quarter performance, marked by solid growth, impressive cash flow attributes, and upcoming catalysts, which were highlighted following the company's earnings announcement.
Despite a modest 1% increase over the consensus estimates for U.S. sales, the significant outperformance outside the U.S. and enthusiasm for the T2 segment were sufficient to propel Insulet shares upward by over 9%, reaching a 12-month high in valuation. Nevertheless, anticipated competition in the T2 space, tubeless systems, and the pharmacy channel may lead to a normalization of the company's valuation multiple.
After Insulet's third-quarter earnings surpassed expectations, it was noted that the Type 2 label expansion in the U.S. at the end of August significantly contributed to robust new customer initiation in September. Moreover, over a quarter of the new U.S. initiations in the third quarter were attributed to patients with Type 2 diabetes.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

摩根士丹利分析师Patrick Wood维持$银休特 (PODD.US)$买入评级，并将目标价从234美元上调至317美元。

根据TipRanks数据显示，该分析师近一年总胜率为50.0%，总平均回报率为6.8%。

AnalystRecentRatingAutoNews_206393_20241111_833ee7dacd300073de4801116073d624d27a7187_1731407587762980_mm_sc

此外，综合报道，$银休特 (PODD.US)$近期主要分析师观点如下：

Insulet因其强劲的第三季度业绩而获得认可，其特点是稳健的增长、令人印象深刻的现金流属性和即将到来的催化剂，这些都是在公司公布财报后重点介绍的。
尽管美国销售额比市场普遍预期略有增长1％，但美国以外的显著跑赢大盘以及对T2细分市场的热情足以推动Insulet股价上涨9％以上，达到12个月高点。尽管如此，T2领域、无内胎系统和药房渠道的预期竞争可能会导致公司估值倍数的正常化。
在Insulet第三季度收益超出预期之后，有人指出，8月底美国Type 2品牌的扩张为9月份新客户的强劲增长做出了重大贡献。此外，美国在第三季度启动的新药中有四分之一以上归因于2型糖尿病患者。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $317

Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $317

快讯

重估中国资产

热门讨论

Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $317

Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $317

风险及免责提示

快讯

重估中国资产

热门讨论

声明